Finoriq research workspace
Jade Biosciences, Inc. (JBIO) Historical Metrics
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation. Review JBIO valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
- Company
- Jade Biosciences, Inc. (JBIO)
- Ticker
- JBIO
- Market Cap
- $966M
- Latest Price
- $19.57
- Industry
- Biotech & Pharma
Jade Biosciences, Inc. (JBIO) Current Valuation Metrics
Static valuation preview for Jade Biosciences, Inc. (JBIO). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -11.5% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -8.5% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 3.34x | Stockholders' Equity | FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.